Viracta Therapeutics 주식 (NASDAQ: VIRX)

에 대한 최신 뉴스 Viracta Therapeutics (NASDAQ:VIRX) 주식

Viracta Therapeutics

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Asset Sales

Legal

AMPS

BABA

BIGGQ

COEP

CPNG

VIRX

파산 블록 모든 것을 축하할 수 있는 원스톱 상점인 파티 시티 홀드코(Party City Holdco Inc.)가 사업 정리를 하고 있다. 회사 내 700개 매장에서 폐업 세일을 진행하고 있다.

딜 디스패치: 파티 시티 사업 정리, 빅랏츠 파산, 더 컨테이너 스토어 계속 영업 등

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AREN

CSTM

EVAX

GDYN

GEAR

금요일(27일) 아침 미국 주식 선물이 하락하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 몇 가지 주식은 다음과 같다. 콘스텔리움, 비락타 테라퓨틱스, 에바종 바이오테크, 아레나 및 그리드 다이나믹

금요일 주목해야 할 주식: 콘스텔리움, 비락타 테라퓨틱스, 에바종 바이오테크, 아레나 및 그리드 다이나믹

Viracta Therapeutics, Inc. - Common Stock

Viracta Therapeutics Inc

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.03% on an annualized basis producing an average annual return of 14.45%. Currently, Eli Lilly has a market capitalization of $740.34 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 20 years ago, it would be worth $1,476.91 today based on a price of $823.23 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738280753_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Donald Fandetti maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Overweight and lowers the price target from $12 to $11.

Price Target

Analyst Ratings

AGNC

Wells Fargo Maintains Overweight on AGNC Investment, Lowers Price Target to $11

Billionaire Jeff Bezos appears to have a major conflict of interest on his hands with a newspaper he owns trying to get records from another<a href="https://www.benzinga.com/news/21/04/20675447/5-things-you-might-not-know-about-jeff-bezos"> company he founded.</a>
What Happened: While he's <a href="https://www.benzinga.com/news/21/07/21849808/jeff-bezos-is-officially-no-longer-the-amazon-ceo">no longer the CEO</a> of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Bezos remains a shareholder and the executive chairman of the company.
This means that a lawsuit filed by Amazon against the Washington Post, which Bezos owns, now has the billionaire on both sides of the legal fight.
The Washington Post is trying to obtain records related to Amazon's Project Kuiper satellite business, <a href="https://www.hollywoodreporter.com/business/business-news/jeff-bezos-amazon-sues-block-records-requests-washington-post-1236121933/">according </a>to The Hollywood Reporter.
Amazon is fighting back and has sued to block the records request as the e-commerce company states releasing the information could be harmful as it contains trade secrets.
The report says items requested by the news outlet include inspection records, investigation notes and complaints related to visits to the company by the Washington Department of Labor and Industries.
Amazon says the records contain proprietary satellite designs and other information that could give competitors "a competitive edge."
Amazon has not sued the newspaper directly, instead filing a lawsuit against a Washington state agency that agreed to disclose the records. The company is not seeking to block the release of all of the requested records, only a small portion that it believes contains trade secrets.
You may not be a billionaire like Jeff Bezos, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/01/43201590/benzinga-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-2">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: The news of the battle by The Washington Post against Amazon comes as the newspaper faces public pushback after <a href="https://www.benzinga.com/general/politics/24/10/41557083/jeff-bezos-ends-washington-posts-36-year-tradition-of-endorsements-leaving-staff-roiled">not endorsing a candidate </a>for president for the first time since 1988.
The decision was said to have been made by Bezos, who bought the newspaper in 2013. The move led to the exit of several newspaper workers and saw around 250,000 subscribers cancel their subscriptions as a result.
The battle between The Washington Post and Amazon and the outcome could become a storyline for Bezos and whether or not billionaires should own news outlets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/09/41107170/jeff-bezos-used-this-method-to-get-true-opinions-from-employees-amazon-founder-says-youre-the-b">Jeff Bezos Used This Method To Get True Opinions From Employees: Amazon Founder Says &#8216;You&#8217;re The Boss&#8217;</a></li>
</ul>
Photos: Shutterstock

SPACE

Media

AMZN

Bezos Vs. Bezos: Amazon Files Lawsuit Related To Washington Post In Major Conflict Of Interest For Billionaire

Wells Fargo analyst Larry Biegelsen maintains NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Overweight and raises the price target from $13 to $17.

NPCE

Wells Fargo Maintains Overweight on NeuroPace, Raises Price Target to $17

Wells Fargo analyst Ike Boruchow maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Equal-Weight and lowers the price target from $45 to $40.

VSCO

Wells Fargo Maintains Equal-Weight on Victoria's Secret, Lowers Price Target to $40

Wells Fargo analyst Matthew Akers maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Overweight and raises the price target from $151 to $156.

Wells Fargo Maintains Overweight on RTX, Raises Price Target to $156

Wells Fargo analyst Matthew Akers maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Equal-Weight and lowers the price target from $500 to $497.

Wells Fargo Maintains Equal-Weight on Lockheed Martin, Lowers Price Target to $497

Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Equal-Weight and lowers the price target from $8 to $6.

ZNTL

Wells Fargo Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $6

Wells Fargo analyst Zachary Fadem maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Equal-Weight and raises the price target from $145 to $175.

Wells Fargo Maintains Equal-Weight on Brinker International, Raises Price Target to $175

Wells Fargo analyst David Lantz maintains Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) with a Equal-Weight and lowers the price target from $24 to $20.

MNRO

Wells Fargo Maintains Equal-Weight on Monro, Lowers Price Target to $20

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 6.96% on an annualized basis producing an average annual return of 19.23%. Currently, Blackstone has a market capitalization of $135.00 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 15 years ago, it would be worth $13,976.42 today based on a price of $177.82 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738279807_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Wells Fargo analyst Ike Boruchow maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Underweight and raises the price target from $17 to $21.

Wells Fargo Maintains Underweight on VF, Raises Price Target to $21

UBS analyst Alex Kramm maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and raises the price target from $79 to $89.

NDAQ

UBS Maintains Neutral on Nasdaq, Raises Price Target to $89

UBS analyst Gregg Orrill maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Buy and lowers the price target from $24 to $22.

UBS Maintains Buy on PG&E, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $30 to $27.

TEVA

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $27

UBS analyst Timothy Arcuri maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral and lowers the price target from $78 to $70.

UBS Maintains Neutral on Western Digital, Lowers Price Target to $70

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has turned increasingly political in recent years, a move that may have hurt the brand value of the <a href="https://www.benzinga.com/news/global/25/01/43172806/tesla-lost-15-billion-in-brand-value-in-2024-report-says-did-elon-musks-political-push-hurt-ev-giant">electric vehicle company.</a>
While Musk is OK with supporting President Donald Trump and the end of the $7,500 federal tax credit, the billionaire also has his eyes set on a sustainable future.
What Happened: A proposed end to the <a href="https://www.benzinga.com/trading-ideas/25/01/43116755/trumps-plan-to-end-7500-ev-tax-credits-could-be-devastating-for-telsa-rivals-poll-says-could-be-bullish-for-elon-musks-company">$7,500 EV tax credit </a>by Trump is one of the biggest storylines for the electric vehicle sector and Musk is a supporter of making such a change.
Musk and Tesla analysts believe the decision to end the credit would be bad for Tesla in the short term, but ultimately benefit the company in the long term as it would be tougher on competitors.
The Tesla CEO was asked about electric vehicle policies under Trump during the company's<a href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal-year"> fourth-quarter earnings call.</a>
An analyst asked about plans to reverse the "EV mandate" and potential slowdowns of electric vehicle demand in the U.S. due to regulations.
Musk shied away from the question but did highlight his continued belief on electric vehicles being a big part of the future.
"At this point, I think that sustainable transport is inevitable," Musk said, as shared by <a href="https://insideevs.com/news/749018/musk-q4-call-ev-regulations/">InsideEVs</a>. "I'm highly confident that all transport will be autonomous, electric, including aircraft, and that simply, it can't be stopped."
Musk went on to compare the rise of electric vehicles to the introduction of the internal combustion engine.
"Even if you've been the biggest horse advocate on Earth … like, ‘horses are the way, not these new-fangled automobiles,' you can't stop the advent of the automobile and you can't stop the advent of electric cars. It's going to happen."
The Tesla CEO said the only thing holding back electric vehicles previously was range, which has been solved.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While investors and analysts wanted to hear about Musk's relationship with Trump, what his role<a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently"> at the D.O.G.E. </a>means for his time commitment at Tesla and how Trump's EV policies could shape the industry, the earnings call left many questions unanswered.
Trump has been a vocal critic of electric vehicles and also previously said he would ban autonomous vehicles from U.S. roads, a move that would severely hurt the future growth plan of Tesla and its robotaxis.
New Transportation Secretary Sean Duffy shared in a memo that the previous push by Joe Biden's administration for electric vehicles was "forced" on people.
Musk's comments about the future being all-electric and autonomous go against the commentary of Trump and his administration, which could make the friendship between the billionaire and president an interesting development to watch as Musk will likely have to push for support of autonomous vehicles.
Rivian Automotive CEO RJ Scaringe recently <a href="https://www.benzinga.com/25/01/43279098/rivian-ceo-brushes-off-7500-electric-vehicle-tax-credit-concerns-evs-are-not-a-political-thing">shared a similar commentary</a> of keeping his eyes on the future and ignoring the short-term "speed bumps" created by items like the end of the federal tax credit.
&#8220;I started the company with the view of making highly compelling products, and none of my decision to start Rivian had anything to do with what the policy was going to look like,&#8221; Scaringe said.
Scaringe said that the potential elimination of the $7,500 tax credit would be &#8220;equally applied to all,&#8221; which could mean a level playing field for all companies in the electric vehicle sector.
&#8220;The future of transportation will be electric.&#8221;
Scaringe said policy revisions like this can&#8217;t slow down the long-term trend of electric vehicle growth and the necessity of having more electric vehicles on the road.
&#8220;This is not a political thing. It&#8217;s not like the left wants to move to electrification. It&#8217;s that the future of transportation will be electric.&#8221;
Watch the Tesla fourth-quarter earnings call with Musk below. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43347509/tesla-stock-analysts-highlight-fsd-robotaxis-new-vehicles-for-growth-elon-has-never-sounded-so-bullish">Tesla Analysts Highlight FSD, Robotaxis, New Vehicles For Growth: &#8216;Elon Has Never Sounded So Bullish&#8217;</a></li>
</ul>
Photo: Shutterstock
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Tesla Q4 2024 Earnings Call &#x7C; $TSLA" width="500" height="281" src="https://www.youtube.com/embed/G2UrBRGrLb0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Earnings

Politics

TSLA

Elon Musk Brushes Aside Concerns On Trump's EV Policies: 'Sustainable Transport Is Inevitable … It Can't Be Stopped'

UBS analyst Karl Keirstead maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and lowers the price target from $525 to $510.

MSFT

UBS Maintains Buy on Microsoft, Lowers Price Target to $510

UBS analyst Jay Sole maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and raises the price target from $24 to $28.

UBS Maintains Neutral on VF, Raises Price Target to $28

UBS analyst Lloyd Walmsley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $736 to $786.

UBS Maintains Buy on Meta Platforms, Raises Price Target to $786

Viracta Therapeutics (VIRX) announced that the company has implemented a reprioritization of resources intended to enhance the company's focus on i...

Viracta Therapeutics reports 42% reduction in force, strategic reprioritization

"Last quarter, based on productive feedback from FDA, we announced a sharpened focus on the second-line EBV-positive PTCL subpopulation in the NAVA...

Viracta Therapeutics reports Q3 EPS (27c) vs (33c) last year

Cash, cash equivalents, and short-term investments totaled approximately $21.1 million as of September 30, 2024, which Viracta expects will be suff...

Viracta Therapeutics expects cash to fund operations into Q1 of 2025

Viracta Therapeutics GAAP EPS of -$0.27 misses by $0.03

Viracta Therapeutics (VIRX) announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives. To ma...

Viracta Therapeutics announces exploration of strategic alternatives

Viracta Therapeutics ( ($VIRX) ) just unveiled an update. Viracta Therapeutics has announced the closure of its NAVAL-1 clinical trial for Nana-val...

Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure

Rodman & Renshaw downgraded Viracta Therapeutics (VIRX) to Neutral from Buy with a price target of 25c, down from $3.50, after Viracta announced it...

Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw

Viracta falls on plans to explore strategic options

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Netflix (NFLX) says Christmas NF...

Netflix draws big viewership for NFL Christmas games: Morning Buzz

AMED

BGNE

CDTG

CRKN

GOOG

GOOGL

HMST

IMKTA

LAES

MYSZ

NFLX

OKLO

OTLK

PGNY

SNEJF

SONY

TTAN

UBER

Press Releases

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Management

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics Announces New Employment Inducement Grants

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Health Care

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aptevo Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Galecto

Genprex

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Onconetix

Organovo Holdings

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Plus Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Soligenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

T2 Biosystems

Xenetic Biosciences

Rodman & Renshaw

RBC Capital

Leerink Partners

Oppenheimer

HC Wainwright & Co.

<h2 class="wp-block-heading">파산 블록</h2>
모든 것을 축하할 수 있는 원스톱 상점인 파티 시티 홀드코(Party City Holdco Inc.)가 사업 정리를 하고 있다. 회사 내 700개 매장에서 폐업 세일을 진행하고 있다.
파티 시티가 2년 만에 챕터 11 파산 보호를 신청한 것은 이번이 두 번째이다. 2023년에는 구조 조정 과정을 통해 거의 10억 달러에 달하는 부채가 제거되었다. 이는 이 회사를 계속 유지하기에 충분하지 않았다.
파티 시티는 또한 인플레이션과 같은 심각한 소동에 직면했으며, 이 체인의 창립자인 스티브 맨델(Steve Mandell)과의 뉴요 포스트  <a href="https://nypost.com/2023/01/25/party-citys-founder-blames-bankruptcy-on-private-equity-firms/" target="_blank" rel="noopener">인터뷰</a>에 따르면 조잡한 리더십에 직면했다.
파티 시티는 캐피털 그룹(Capital Group), 데이비슨 켐프너(Davidson Kempner) 및 실버 포인트 캐피털(Silver Point Capital)과 같은 투자 회사들이 소유하고 있다.
뉴저지 주 우드클리프 레이크에 본사를 둔 이 회사는 텍사스 남부 지역의 미국 파산 법원에 챕터 11을 신청했다.
파티 시티의 직원 12,000명 중 95% 이상이 대규모 청산 작업을 돕기 위해 <a href="https://www.cnn.com/2024/12/20/business/party-city-shut-down/index.html" target="_blank" rel="noopener">2월 28일</a>까지 남아 있을 것이다.
파티 시티의 폐업 소식은 파산한 소매업체 빅랏츠(OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/biggq" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BIGGQ">BIGGQ</a>)가 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42624759/big-lots-holds-liquidation-sales-analyst-pegs-competitor-as-major-beneficiary-market-share-capture-opportunity" target="_blank" rel="noopener" data-google-interstitial="false">구매자를 찾지 못한 지</a> 불과 며칠 만에 나왔다.
이 소매업체는 지난 9월 사모펀드 넥서스 캐피털 매니지먼트(Nexus Capital Management)에 자산을 매각할 예정이라고 발표한 바 있다. 그러나 이제 거래는 거의 불가능하다.
진정한 정리 세일 정신으로 회사는 &#8216;폐업&#8217; 폭발을 일으키고 있다. 또한 다른 옵션을 탐색하여 희망을 유지하고 있다. 이것이 넥서를 다시 테이블로 끌어들이는 것인지 아니면 새로운 구매자를 찾는 것인지는 아직 알 수 없다.
그게 다가 아니다. <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%8A%A4%ED%86%A8%EB%A6%AC-%EB%AF%B8%EA%B5%AD-%EC%82%AC%EC%97%85%EB%B6%80-%ED%8C%8C%EC%82%B0-%EB%B3%B4%ED%98%B8-%EC%8B%A0%EC%B2%AD-%EC%95%A8%EB%A6%AC/" target="_blank" rel="noopener">벤징가 딜 디스패치</a>는 지난달 보도한 바에 따르면 더 컨테이너 스토어(The Container Store)는 파산 위기에 처해 있었다. 비욘드(Beyond Inc.)와 <a href="https://www.benzinga.com/markets/equities/24/10/41356027/whats-going-on-with-container-store-stock-after-getting-40m-investment-from-beyond" target="_blank" rel="noopener" data-google-interstitial="false">거래를 체결할 수 없었던</a> 방법을 기억해 보자. 이 <a href="https://www.businesswire.com/news/home/20241222725949/en/The-Container-Store-to-Execute-Comprehensive-Recapitalization-Transaction-with-Lender-Support-to-Best-Position-the-Company-for-Future-Success" target="_blank" rel="noopener">서류</a>는 12월 22일 일요일 텍사스 지방 법원에서 공식화되었다.
그러나 파티 시티 및 빅랏츠와는 달리 더 컨테이너 스토어는 계속 영업을 하고 있다.
더 컨테이너 스토어의 CEO인 사티쉬 말호트라(Satish Malhotra)는 &#8220;우리의 전략은 타당하다&#8221;고 말했다.
이 사랑받는 스토리지 솔루션 및 재택 서비스 제공업체가 재정을 정리하고 있다. 이 회사의 정기 대출 기관 중 최대 90%가 거래 지원 계약에 동참했다.
더 컨테이너 스토어는 4,000만 달러의 신규 자금을 확보하고 4,500만 달러의 부채를 삭감하게 된다. 이 모든 것은 더 컨테이너 스토어가 파트너, 공급업체 및 이해관계자들과의 약속을 차질 없이 지키는 것을 목표로 하고 있음을 의미한다.
이 회사는 향후 30일 이내에 파산을 종료할 것으로 예상하고 있다. 다시 등장하면 개인 회사가 될 것다.
스웨덴에 있는 더 컨테이너 스토어의 엘파(Elfa) 사업은 영향을 받지 않는다.
<h2 class="wp-block-heading">블록에 신규 등장</h2>
비락타 테라퓨틱스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/virx" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for VIRX">VIRX</a>)가 매각을 고려하고 있다. 바이러스 관련 암에 초점을 맞춘 이 종양학 회사는 전략적 검토의 일환으로 이 프로세스를 발표했다. 비락타는 재발성/불응성 EBV+ 림프종에 대한 Nana-val의 중추적인 2상 NAVAL-1 시험을 새로운 안전성 문제를 언급하지 않고 자발적으로 종료했다. CEO 마크 로테라(Mark Rothera)는 Nana-val의 향후 승인에 대해 여전히 낙관적이다.
<h2 class="wp-block-heading">블록의 업데이트</h2>
12월 23일 로이터 통신은 인수 회사인 TPG가 상업용 부동산 소유자 및 주거용 주택에 태양 에너지 공급업체인 알터스 파워(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/amps" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for AMPS">AMPS</a>)를 인수하기 위해 협상 중이라고 보도했다. 경쟁 입찰이 나타날 수 있다.
알리바바 그룹 홀딩(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/baba" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BABA">BABA</a>)은 약 40억 달러 규모의 거래를 통해 한국 사업장을 신세계 그룹의 이마트(E-Mart Inc.)와 <a href="https://www.benzinga.com/news/24/12/42680655/alibaba-nears-4b-e-commerce-merger-with-south-koreas-e-mart-report" target="_blank" rel="noopener" data-google-interstitial="false">합병할 예정</a>이다. 이러한 전략적 움직임은 경쟁이 치열한 한국의 온라인 소매 시장에서 입지를 강화하는 것을 목표로 한다. 이 잠재적인 합작 투자는 두 회사의 전자상거래 자산을 결합하는 것이다. 블룸버그는 목요일에 논의가 진행 중이라고 <a href="https://www.bloomberg.com/news/articles/2024-12-26/alibaba-is-said-to-near-4-billion-deal-with-korea-s-e-mart" target="_blank" rel="noopener">보도</a>했다.
<h2 class="wp-block-heading">블록의 메모</h2>
베인 앤 컴퍼니(Bain &amp; Co.)에 따르면 2024년에는 사모펀드 및 금융 투자자들이 새로운 관심을 보였다. 거래 가치는 <a href="https://www.benzinga.com/topic/interest-rates" target="_blank" rel="noopener" data-google-interstitial="false">약간 낮은 이자율</a>로 인해 전년 대비 29% 증가했다.
사소한 부채 비용 변화의 영향을 덜 받는 기업 M&amp;A는 2023년보다 12% 더 높은 한 해를 마무리할 것으로 예상되며 모든 지역에서 거래량이 7% 증가할 것이라고 이 회사가 밝혔다.
&#8220;전체적으로 M&amp;A 활동 수준은 중간 수준인 3조 5천억 달러였다&#8221;고 이 회사가 지적했다. &#8220;2010년대 중반에 우리가 본 것과 일치하는 수치이다.&#8221;
&#8212;
지난주의 &#8216;딜 디스패치&#8217;에 대한 자세한 내용은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%ED%97%88%EB%8B%88%EC%9B%B0-%ED%85%8D%EC%8A%A4%ED%8A%B8%EB%A1%A0-%EB%94%94%EB%A1%9C%EC%BB%AC-%EB%B0%8F-%EC%86%8C%ED%98%B8-%ED%95%98%EC%9A%B0%EC%8A%A4/" target="_blank" rel="noopener">여기를 클릭하세요</a>.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금요일(27일) 아침 미국 주식 선물이 하락하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 몇 가지 주식은 다음과 같다.
1. 콘스텔리움 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSTM#NYSE">CSTM</a>)
콘스텔리움은 보통주 공모를 발표했다. 이로 인해 시간외 거래에서 3.4% 하락한 10.00달러에 거래되었다.
2. 비락타 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>)
비락타 이사회가 폭넓은 전략적 대안 모색 절차를 시작했다고 발표했다. 현재 진행 중인 재발성/불응성 EBV + 림프종 환자를 대상으로 한 나나-발(Nana-val)의 중추적인 임상 2상 시험을 종료할 계획이라고도 밝혔다. 시간외 거래에서 13.9% 하락한 0.2040달러를 기록했다.
3. 에바종 바이오테크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>)
에바종은 임질균(Neisseria gonorrhoeae)을 표적으로 하는 백신에 대한 특허를 출원했다. 주가는 시간외 거래에서 104.5% 상승한 1.73달러를 기록했다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
4. 아레나 그룹 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NASDAQ">AREN</a>)
아메리카증권거래소(NYSE American)가 아레나 그룹의 컴플라이언스 계획을 승인했다고 발표했다. 주식은 시간외 거래에서 17.6% 상승한 1.67달러를 기록했다.
5. 그리드 다이나믹 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDYN#NASDAQ">GDYN</a>)
그리드 다이나믹은 1월 2일(목) 개장 전 S&amp;P 스몰캡 600 지수에서 레벨리스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEAR#NYSE">GEAR</a>)를 대체할 예정이다. 그리드 다이나믹 주가는 시간외 거래에서 9.7% 상승한 23.11달러를 기록했다.
사진 출처: Wikimedia
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Viracta Therapeutics

뉴스

에 대한 최신 뉴스 Viracta Therapeutics (NASDAQ:VIRX) 주식

토요일, 12월 28, 2024

금요일, 12월 27, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌